Remeditex Ventures LLC recently stated that they own a 6.6% stake in Venaxis Inc. (NASDAQ:APPY) in a Schedule 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, September 19th. The investor owns 295,210 shares of the stock valued at approximately $1,322,541. The reporting parties listed on the disclosure included Remeditex Ventures LLC, Malachite Trust and Lyda Hill. The disclosure is available through Edgar at this link.

Venaxis Inc. (NASDAQ:APPY) traded up 0.4487% during mid-day trading on Monday, hitting $4.5001. 101,355 shares of the company were exchanged. The company’s 50-day moving average is $3.44 and its 200 day moving average is $3.14. Venaxis Inc. has a 12-month low of $1.60 and a 12-month high of $6.65. The company’s market capitalization is $17.44 million.

About Venaxis

Venaxis, Inc (Venaxis) is an in vitro diagnostic company that is focused on commercializing its blood-based test to serve as an adjunctive test in the diagnosis and treatment of acute appendicitis in children, adolescent and young adults. The Company’s test, the APPY1 Test, is a blood test panel for aiding in identifying patients in the emergency department that are at low risk for acute appendicitis.

5 Day Chart for NASDAQ:APPY

Want to see what other hedge funds are holding APPY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Venaxis Inc. (NASDAQ:APPY).

Receive News & Ratings for Venaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venaxis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.